The role of patient’s adherence in the treatment of hyperphosphatemia in chronic kidney disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. evaluation of the adherence to the correction of hyperphosphatemia in patients with chronic kidney disease. the development of hyperphosphatemia is a frequent occurrence among patients with chronic kidney disease, mainly at the terminal stage. Hyperphosphatemia is associated with higher rates of morbidity and mortality. patient’s adherence to the treatment of hyperphosphatemia plays an essential role in the success of the correction of this condition. in this review, five groups of factors that influence adherence to the treatment are examined in detail; they include patient’s characteristics; characteristics of disease; methods of the treatment, its pharmacoeconomic features; the effectiveness of the interaction between the attending physician and the patient.

Full Text

Restricted Access

About the authors

A. M Esayan

Pavlov University

Email: essaian.ashot@gmail.com
Doctor of Medical Sciences, Professor, Head of the Department of Nephrology and Dialysis FPGE Saint-Petersburg, Russia

A. R Rind

Pavlov University

Email: anastasiia.rind@gmail.com
Postgraduate Student at the Department of Nephrology and Dialysis FPGE Saint-Petersburg, Russia

References

  1. Settineri S., Frisone F., Merlo E.M., et al. Compliance, adherence, concordance, empowerment, and self-management: five words to manifest a relational maladjustment in diabetes. Journal of Multidisciplinary Healthcare. 2019;12:299-314.
  2. World Health Organization (2003): Adherence to long-term therapies, evidence for action. Geneva: https://www.who.int/chp/knowledge/publications/ adherence_report/en/
  3. Anghel L.A., Farcas A.M., Oprean R.N. An overview of the common methods used to measure treatment adherence. Medicine and Pharmacy Reports. 2019;92(2):117-122.
  4. Вольская Е.А. Пациентский комплаенс. Обзор тенденций в исследованиях. Ремедиум. 2013;7:6-14.
  5. Messa P, Cerutti R., Brezzi B., Alfieri C., Cozzolino M.: Calcium and phosphate control by dialysis treatments. Blood. Purif. 2009;27:360-368.
  6. Gallieni M., De Luca N., Santoro D., Meneghel G., Formica M., Grandaliano G., Pizzarelli F, Cossu M., Segoloni G., Quintaliani G., Di Giulio S., Pisani A., Malaguti M., Marseglia C., Oldrizzi L., Pacilio M., Conte G., Dal Canton A., Minutolo R. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. J. Nephrol. 2016;29:71-78.
  7. Ketteler M., Block G.A., Evenepoel P., Fukagawa M., Herzog C.A., McCann L., Moe S.M., Shroff R., Tonelli M.A., Toussaint N.D., Vervloet M.G., Leonard M.B. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update. Ann. Int. Med. 2018;168:422-430.
  8. KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int. 2017; 7(1):S1-S59.
  9. Tentori F., Wang M., Bieber B.A., Karaboyas A., Li Y., Jacobson S.H., Andreucci V.E., Fukagawa M., Frimat L., Mendelssohn D.C., Port F.K., Pisoni R.L., Robinson B.M. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. CJASN 2015;10:98-109.
  10. Palmer S., Vecchio M., Craig J.C., Tonelli M., Johnson D.W., Nicolucci A., Pellegrini F., Saglimbene V., Logroscino G., Fishbane S., Strippoli G.F. Prevalence of depression in chronic kidney disease: systematic review and metaanalysis of observational studies. Kidney Int. 2013;84:179-191.
  11. Bolasco P.G., Ghezzi P.M., Ferrara R., Maxi a M., Pinna M., Logias F., Cogoni G., Cadinu F, Ghisu T., Contu B., Casu D., Passaghe M., Pilloni A., Ganadu M., Gazzanelli L. Effect of on-line hemodiafiltration with endogenous reinfusion (HFR) on the calcium-phosphorus metabolism: medium-term effects. Int. J. Artif. Organs. 2006;29:1042-1052.
  12. Messa P., Gropuzzo M., Cleva M., Boscutti G., Mioni G., Cruciatti A., Mazzolini S., Malisan M.R. Behaviour of phosphate removal with different dialysis schedules. Nephrol Dial. Transplant. 1998;13(6):43-48.
  13. Eloot S., Van Biesen W., Dhondt A., Van de Wynkele H., Glorieux G., Verdonck P., Vanholder R. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int. 2008;73:765-770.
  14. Ayus J.C., Mizani M.R, Achinger S.G., Thadhani R., Go A.S., Lee S. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J. Am. Soc. Nephrol. 2005;16:2778-2788.
  15. Daugirdas J.T., Chertow G.M., Larive B., Pierratos A., Greene T., Ayus J.C., Kendrick C.A., James S.H., Miller B.W., Schulman G., Salusky I.B., Kliger A.S. Frequent Hemodialysis Network (FHN) Trial Group: Effects of frequent hemodialysis on measures of CKD mineral and bone disorders. J. Am. Soc. Nephrol. 2012;23:727-738.
  16. Lornoy W., De Meester J., Becaus I., Billiouw J.M., Van Malderen P.A., Van Pottelberge M. Impact of convective flow on phosphorus removal in maintenance hemodialysis patients. J. Renal. Nutr. 2006;16:47-53.
  17. Davenport A., Gardner C., Delaney M. Pan Thames Renal Audit Group: The effect of dialysis modality on phosphate control: haemodialysis compared to haemodiafiltration. Thepan thames renal audit. Nephrol. Dial. Transplant. 2010;25:897-901.
  18. Pedrini L.A., De Cristofaro V., Comelli M., Casino F.G., Prencipe M., Baroni A., Campolo G., Manzoni C., Coli L., Rggiero P., Acquistapace I., Auriemma L. Long-term effects of high-efficiency on-line haemodiafiltration on uraemic toxicity. A multicentre prospective randomized study. Nephrol. Dial. Transplant. 2011;26:2617-2624.
  19. Penne E.L., van der Weerd N.C., van den Dorpel M.A., Grooteman M.P., Levesque R., Nube M.J., Bots M.L., Blankestijn P.J., ter Wee P.M. CONTRAST Investigators: Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled convective transport study (CONTRAST). Am. J. Kidney Dis. 2010;55:77-87.
  20. Cupisti A., Gallieni M., Rizzo M.A., Caria S., Meola M., Bolasco P. Phosphate control in dialysis. Int J. Nephrol. Renovasc. Dis. 2013;6:193-205.
  21. Robinson B.M., Akizawa T., Jager K.J., Kerr P.G., Saran R., Pisoni R.L. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet. 2016;388(10041):294-306.
  22. Kugler C., Maeding I., Russell C.L. Non-adherence in patients on chronic hemodialysis: an international comparison study. J Nephrol. 2011;24(3):366-375.
  23. Martins M.T., Silva L.F., Kraychete A., et al. Potentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis. BMC Nephrol. 2013;14:208
  24. Bleyer A.J., Hylander B., Sudo H., et al. An international study of patient compliance with hemodialysis. JAMA. 1999;281(13):1211-1213.
  25. Leggat J.E. Jr. Adherence with dialysis: a focus on mortality risk. Semin. Dial. 2005;18(2):137-141.
  26. Obialo C.I., Hunt W.C., Bashir K., Zager P.G. Relationship of missed and shortened hemodialysis treatments to hospitalization and mortality: observations from a US dialysis network. Clin. Kidney J. 2012;5(4):315-319.
  27. Al Salmi I., Larkina M., Wang M., Subramanian L., Morgenstern H., Jacobson S., Hakim R., Tentori F., Saran R., Akiba T., Tomilina N.A., Port F., Robinson B., and Pisoni R. Missed Hemodialysis Treatments: International Variation, Predictors, and Outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS). AJKD. 2018;72(5):635-43
  28. Obialo C.I., Hunt W.C., Bashir K., Zager P.G. Relationship of missed and shortened hemodialysis treatments to hospitalization and mortality: observations from a US dialysis network. Clin Kidney J. 2012;5(4):315-319
  29. Brar A., Babakhani A.,Salifu M.O., Jindal R.M. Evaluation of non-adherence in patients undergoing dialysis and kidney transplantation: United States transplantation practice patterns survey. Transplant. Proc. 2014;46:1340-1346
  30. Chan K.E., Thadhani R.I., Maddux F.W. Adherence barriers to chronic dialysis in the United States. J. Am. Soc. Nephrol. 2014;25(11):2642-2648
  31. Kalantar-Zadeh K, Gutekunst L., Mehrotra R., Kovesdy C.P., Bross R., Shinaberger C.S., et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010;5:519-30
  32. Cupisti A., Kalantar-Zadeh K. Management of natural and added dietary phosphorus burden in kidney disease. Semin. Nephrol. 2013;33(2):180-90.
  33. Karp H, Ekholm P, Kemi V., Itkonen S., Hirvonen T., Narkki S, et al. Differences among total and in vitro digestible phosphorus content of plant foods and beverages. J. Ren. Nutr. 2012;22(4):416-22.
  34. Jones W.L. Demineralization of a wide variety of foods for the renal patient. J. Ren. Nutr. 2001;11:90-6.
  35. Benini O., Alessandro C., Gianfaldoni D., Cupisti A. Extra-phosphate load from food additives in commonly eaten foods: a renal and insidious danger for renal patients. J. Ren. Nutr. 2011;21:303-8.
  36. Leon J.B., Sullivan C.M., Sehgal A.R.: The prevalence of phosphorus-containing food additives in top-selling foods in grocery stores. J. Renal. Nutr. 2013;23:265-270.
  37. Bump M. Organic phosphorus versus inorganic phosphorus: empowering adult kidney patients with nutrition education. J. Renal. Nutr. 2016;26:31-3.
  38. Leon J.B., Sullivan C.M., Sehgal A.R. The prevalence of phosphorus-containing food additives in top-selling foods in grocery stores. J. Ren. Nutr. 2013;23(4):265-70.
  39. Sullivan C., Sayre S.S., Leon J.B., Machekano R., Love T.E., Porter D., et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA. 2009;301(6):629-35.
  40. Shutto Y., Shimada M., Kitajima M., Yamabe H., Saitoh Y., Saitoh H, et al. Inadequate awareness among chronic kidney disease patients regarding food and drinks containing artificially added phosphate. PLoS One. 2013;8(11).
  41. Caldeira D., Amaral T., David C., Sampaio C. Educational strategies to reduce serum phosphorus in hyperphosphatemic patients with chronic kidney disease: systematic review with meta-analysis. J. Ren. Nutr. 2011;21(4):285-94.
  42. Kalantar-Zadeh K. Patient education for phosphorus management in chronic kidney disease. Patient Prefer Adherence. 2013;7:379-90.
  43. Serfaty M.A., Haworth D., Blandhard M., Buszewicz M., Murad S., King M. Clinical effectiveness of individual cognitive behavioral therapyfor depressed older people in primary care: a randomized controlled study. Arch. Gen. Psychiatry. 2009;66(12):1332-1340.
  44. Fournet R.M. Technology and applications: how can they help dietitians? Ren. Nutr. Forum. 2014;33:1-6.
  45. Kahan S., Manson J.E. Nutrition counseling in clinical practice: how clinicians can do better. JAMA. 2017;318:1101-1102.
  46. DAlessandro C., Piccoli G., Cupisti A. The “phosphorus pyramid”: a visual tool for dietary phosphate management in dialysis and CKD patients BMC Nephrology. 2015,16:9 http://www.biomedcentral.com/1471-2369/16f9
  47. Fernandez-Martin J.L., Carrero J.J., Benedik M., Bos W.J., Covic A., et. al. COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol. Dial. Transplant. 2013;28:1922-1935.
  48. Karamanidou C., Clatworthy J., Weinman J., Horne R. A systematic review of the prevalence anddeterminants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 9:2. doi: 10.1186/1471-2369-9-2 PMID: 18237373
  49. Fissell R.B., Karaboyas A., Bieber B.A., et al. Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS. Hemodial. Int. 2016;20(1):38-49.
  50. Erasmus R.T., Savory J., Wills M.R., Herman M.M.: Aluminum neurotoxicity in experimental animals. Ther. Drug. Monit. 1993;15:588-592.
  51. Spasovski G.B., Sikole A., Gelev S., Masin-Spasovska J., Freemont T., Webster I., Gill M., Jones C., De Broe M.E., D’Haese P.C. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol. Dial. Transplant. 2006;21:2217-2224.
  52. Malluche H.H., Maw ad H., Monier-Faugere M. C. The importance of bone health in endstage renal disease: out of thefrying pan, into the fire? Nephrol. Dial. Transplant. 2004;19(1):i9-i13.
  53. Apetrii M., Covic A., Massy Z.A. Magnesium supplementation: aconsideration in dialysis patients. Semin. Dial. 2018;31:11-14.
  54. Jamal S.A., Vandermeer B., Raggi P., et al. Effect of calcium-based versus noncalcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268.
  55. Patel L., Bernard L.M., Elder G.J. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Clin. J. Am. Soc. Nephrol. 2016;11:232
  56. Floege J., Covic A.C., Ketteler M., et al. Long-term effects of the iron based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol. Dial. Transpl. 2017;32:1918-1926.
  57. Coyne D.W., Ficociello L.H., Parameswaran V., Anderson L., Vemula S., Ofsthun N.J., Mullon C., Maddux F.W., Kossmann R.J. Real-world effectiveness of sucro-ferric oxyhydroxide in patients on chronic hemodialysis: a retrospective analysis of pharmacy data. Clin. Nephrol. 2017;88:59-67.
  58. Chiu Y.W., Teitelbaum I., Misra M., de Leon E.M., Adzize T., Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality o fife in maintenance dialysis patients. Clin. J. Am. Soc. Nephrol. 2009;4:1089-1096.
  59. Daugirdas J.T., Blake P, Ing T. Bone disease. In: Wolters Kluwer Health. Philadelphia, PA Handbook of dialysis. 5th ed. Philadelphia, PA: Wolters Kluwer Health; 2015.
  60. Kalantar-Zadeh K., Parameswaran V., Ficociello L.H., et al. Real-world scenario improvements in serum phosphorus levels and pill burden in peritoneal dialysis patients treated with sucroferric oxyhydroxide. Am. J. Nephrol. 2018;47(3):153-161.
  61. Gray K., Ficociello L., Hunt A., Mullon C., Brunelli S. Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide. International Journal of Nephrology and Renovascular Disease. 2019:121-8
  62. Monaco K., S. Writer Phosphate Binder Type Matters in Dialysis - Hospital admission rates, healthcare costs varied according to binder prescribed. MedPage Today March 28, 2020, National Kidney Foundation 2020. Spring Clinical Meetings.
  63. Coyne D., Ficociello L., Parameswaran V., Rosen M, Sprague S. et al. Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study. Kidney Med. 2020;2(3):307-316.
  64. US DOPPS Practice Monitor. http://www.dopps.org/dpm/.Accessed April 17, 2020.
  65. Floege Ju.Phosphate binders in chronic kidney disease: a systematic review of recent data J. Nephrol. 2016;29:329-340.
  66. Угрехелидзе Д.Т., Ккуликов А.Ю. Фармакоэкономический анализ лекарственного средства Вельфоро® 500 (комплекс в-железа (iii) оксигидроксида, сахарозы и крахмала) в лечении гиперфосфатемии у пациентов с хронической болезнью почек. Фармакоэкономика: теория и практика. 2016;4(1):176-182.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies